Immune Checkpoint Inhibitors Plus an Anti-VEGF Antibody as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis and Cost-Effectiveness Analysis

Background: Sintilimab + a bevacizumab biosimilar (IBI305) (SB) and atezolizumab + bevacizumab (AB) have been approved for the treatment of unresectable hepatocellular carcinoma (HCC). At present, oncologists and their patients remain indecisive on their preferred treatment regime. Therefore, assess...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Lu, Yang, Shilei, Chen, Yanwei, Tian, Li, He, Ying, Wu, Bin, Dong, Deshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198580/
https://www.ncbi.nlm.nih.gov/pubmed/35721168
http://dx.doi.org/10.3389/fphar.2022.891008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198580/
https://www.ncbi.nlm.nih.gov/pubmed/35721168
http://dx.doi.org/10.3389/fphar.2022.891008

Ejemplares similares